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Abstract
Tetralogy of Fallot (TOF) is one of the most common severe congenital heart malformations. Great progress has been made
in identifying key genes that regulate heart development, yet approximately 70% of TOF cases are sporadic and
nonsyndromic with no known genetic cause. We created an ultra high-resolution gene centric comparative genomic
hybridization (gcCGH) microarray based on 591 genes with a validated association with cardiovascular development or
function. We used our gcCGH array to analyze the genomic structure of 34 infants with sporadic TOF without a deletion on
chromosome 22q11.2 (n male = 20; n female = 14; age range of 2 to 10 months). Using our custom-made gcCGH microarray
platform, we identified a total of 613 copy number variations (CNVs) ranging in size from 78 base pairs to 19.5 Mb. We
identified 16 subjects with 33 CNVs that contained 13 different genes which are known to be directly associated with heart
development. Additionally, there were 79 genes from the broader list of genes that were partially or completely contained
in a CNV. All 34 individuals examined had at least one CNV involving these 79 genes. Furthermore, we had available whole
genome exon arrays from right ventricular tissue in 13 of our subjects. We analyzed these for correlations between copy
number and gene expression level. Surprisingly, we could detect only one clear association between CNVs and expression
(GSTT1) for any of the 591 focal genes on the gcCGH array. The expression levels of GSTT1 were correlated with copy
number in all cases examined (r = 0.95, p = 0.001). We identified a large number of small CNVs in genes with varying
associations with heart development. Our results illustrate the complexity of human genome structural variation and
underscore the need for multifactorial assessment of potential genetic/genomic factors that contribute to congenital heart
defects.
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understanding of possible causes will permit insight into the
pathobiological basis of TOF, and allow for improved definition of
disease risk. It may also empower health care practitioners with
improved diagnosis, prognosis, and therapy.
Based on studies of recurrence and transmission risks, it is
hypothesized that the etiology of all CHD (including TOF) is most
likely multifactorial in origin [2,6]. The sporadic nature of most
non-syndromic CHD probably involves a multitude of susceptibility genes with low-penetrance mutations (common variants), or
intermediate-penetrance mutations (rare variants), superimposed
on unfavorable environmental factors. Conceptually, an individual’s genetic configuration interacts with environmental and
epigenetic factors to reach a threshold of ‘‘noise’’ in the cell to
cell communication exceeding the ability of feedback regulatory
mechanisms to compensate, resulting in a congenital heart defect
[7]. Although widely accepted, this hypothesis remains difficult to

Introduction
Tetralogy of Fallot (TOF) consists of a ventricular septal defect,
obstruction of the right ventricular outflow tract, override of the
ventricular septum by the aortic root, and right ventricular
hypertrophy [1]. As the most prevalent form of cyanotic heart
disease, it occurs in about five to seven per 10,000 live births, and
accounts for 5–7% of all congenital heart defects (CHD). The
occurrence of CHD in the offspring of mothers with TOF is
approximately 3.1%, supporting a genetic contribution to the
developmental defect [2–4]. With the tremendous advancements
in surgical and medical management, the morbidity and mortality
of those born with TOF in the last 20 years is significantly
improved. However, long-term sequelae, including ventricular
dysfunction, arrhythmia, and life-long disability, are still challenges
in this patient population [1,5]. As with most congenital heart
defects, the etiology of TOF is poorly understood. Improved
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tissue samples removed during surgery were excised by the
performing surgeon for clinical indications utilizing standard of
care procedures. The normally developing comparison RV tissues
(cryo-preserved pulmonary homografts, described in detail in [25])
were thawed per protocol in sterile conditions. The attending
surgeon (JEO) dissected the normally developing graft tissue to
ensure the graft tissues were from the equivalent location as the
tissue obtained from surgery.

prove, and only a few studies describing accumulation and/or
interaction effects in CHD have been reported [8].
The influence of genetic factors is evident by the association of
TOF with chromosomal abnormalities such as microdeletion of
chromosome 22q11.2, and trisomy 21, 18, or 13 [5]; however,
these patients usually have multiple non-cardiac abnormalities
concurrently with TOF. Multiple genetic studies have shown
many signaling pathways, including WNT, NOTCH, BMP (bone
morphogenetic protein), and FGF (fibroblast growth factor), play
critical regulatory roles in the secondary heart field and contribute
to the formation of the outflow tract and right ventricle [9].
Distinct changes in gene expression in these signaling pathways
have been found in human heart tissues from individuals with
TOF [10]. Haploinsufficiency of cardiac transcription factor genes
that regulate these pathways (NKX2.5, TBX1, TBX5 and GATA4)
or the transmembrane receptors, NOTCH1 and NOTCH2 and
their ligand JAG1, can cause TOF and other heart defects [8]. In
addition, recent genome wide association studies (GWAS) of single
nucleotide polymorphisms in subjects with TOF revealed a
significant associations between SNPs located on chromosomes
12q24.11–13 and 13q32 [11], and 15q26.3 and 18q21.2 [12].
Additionally, somatic mutations that reduce the expression of
GATA6 have been associated with TOF [13].
Most non-syndromic CHDs, which account for 80% of all
CHDs, occur sporadically, and families with clear monogenic
inheritance of non-syndromic CHD are rare. This makes the
identification of human disease genes involved in non-syndromic
CHD by a classical positional genetics approach difficult [8].
There has been great interest in using aCGH to identify copy
number variants (CNVs) that may contribute to CHD [14–22].
GWAS studies and aCGH have identified some new candidate
risk factors for CHD, but there remains a significant amount of
heritability that remains unexplained.
Genome-wide microarray-based comparative genomic hybridization (aCGH) or SNP microarray analysis is now recommended
as a first-tier test for patients with intellectual disabilities, autism,
and/or congenital anomalies [23,24]. Considering that next
generation sequencing (NGS) methods are not yet reliable enough
to detect genomic CNVs; aCGH still represents the gold standard
for identifying pathogenic chromosomal abnormalities as small as
several hundred base pairs, and up to several megabases. We
report our analysis of genomic DNA from 34 infants with sporadic
non-syndromic TOF using a novel ultra high-resolution custom
gene-centric comparative genomic hybridization (gcCGH) microarray. This array was used to identify CNVs involving genes
known to be important for vertebrate heart development and/or
function.

Construction of a Gene Centric Comparative Genomic
Hybridization (gcCGH) Microarray
We used the Ingenuity Pathways Analysis (IPA, Redwood City,
CA) database to derive a list of genes which contained the word
‘‘cardiac’’ or ‘‘heart’’ in their description (2237 IPA genes). In
addition, we derived a refined subset of genes with validated roles
in cardiovascular development or function (594 validated genes)
using the three online databases: Cardiovascular Gene Ontology
Annotation
Initiative
(http://www.ebi.ac.uk/GOA/CVI/
prioritized_gene_list.html); CHD Wiki (http://homes.esat.
kuleuven.be/,bioiuser/chdwiki/index.php/Main_Page);
and
HuGE Navigator (version 2.0) (http://www.hugenavigator.net/
HuGENavigator/startPagePhenoPedia.do). Finally, in order to
focus on genes that are more likely to impact cardiac development,
we used IPA to derive a list of 229 genes that comprise five
networks with experimentally confirmed roles in regulating
vertebrate heart development: WNT; Notch; Sonic Hedgehog;
cardiomyocyte differentiation via BMP receptors; and factors
promoting cardiogenesis in vertebrates (development of these lists
of genes is described in greater detail in [25] and the complete list
is in Table S2).
The ultra high-resolution gene centric microarray was designed
by Oxford Gene technology (OGT, Begbroke, Oxfordshire, UK).
The genes from the five heart development networks and the 594
genes in our validated list were saturated with probes throughout
the length of the gene, provided the sequence met length, GC
content and Tm requirements for the array. The remaining genes
from the IPA search had less dense probe assignment, and the
remaining genome was covered at approximately 1 probe per
9.4 Kb.

Array Hybridization
All gcCGH tests were performed, analyzed and validated
based on the protocols described previously [26,27]. In brief, all
DNA samples were assessed for genomic DNA concentration
and purity. Agarose gel electrophoresis was used to assess the
quality of the genomic DNA samples. The test DNA (3 mg) and
reference DNA (3 mg, pooled normal human male or female
DNAs were used as reference DNA; purchased from Promega,
Madison, WI) were digested with AluI and RsaI (Promega), and
then labeled using the Agilent Genomic DNA Labeling Kit
PLUS (Agilent Technologies, Santa Clara, CA). The individually labeled test and reference samples were then purified using
Microcon YM-30 filters (Millipore, Billerica, MA). Following
purification, the appropriately labeled test DNA and reference
DNA were mixed together and hybridized to the custom
gcCGH array. The hybridization was followed by four washing
steps, and slides were scanned on an Agilent Microarray
Scanner G2565BA with 5-mm resolution. Captured images were
assessed with Feature Extraction Software, version 9.5 (Agilent),
and the data were then imported into Agilent CGH Analytics
3.2.5 software for statistical analysis.

Materials and Methods
Ethics Statement
The Children’s Mercy Hospitals and Clinics institutional review
board approved this research protocol. The parents of all subjects
provided written consent for participation after reading the
consent document and having their questions answered.

Sample Collection
Genomic DNA was extracted from the peripheral blood of 34
infants with sporadic TOF (n male = 20; n female = 14; age range of 2
to 10 months). None of these infants had a 22q11.2 deletion, and
most had no other clinical features (Clinical summary, Table S1).
Gene expression analysis was done on right ventricular (RV) tissue
that was discarded during reconstructive surgery, de-identified,
flash frozen and stored in liquid nitrogen until processing. All
PLOS ONE | www.plosone.org
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as previously described [10,28]. For each sample, real-time q-PCR
or qRT-PCR was performed in triplicate on an ABI 7000
sequence detection instrument. The point at which the intensity
level crossed the PCR cycle threshold (CT) was used to compare
individual reactions. We used RNU24 and GAPDH to normalize
our q-PCR or qRT-PCR results as done previously [10,25,27].

aCGH Analysis
The analysis and visualization of aCGH-244 K data was
performed using the Aberration Detection Method 2 (ADM2)
within Agilent CGH Analytics 3.2.5 software as used in our
clinical laboratory evaluations, and as described in detail
previously [26]. Briefly, the ADM2 quality-weighted interval score
algorithm identifies aberrant intervals in samples that have
consistently high or low log ratios based on their statistical score.
The score represents the deviation of the weighted average of the
normalized log ratios from its expected value of zero calculated
with Derivative Log2 Ratio Standard Deviation algorithm. Our
threshold settings for the CGH analytics software to make a
positive call were 6.0 for sensitivity, 0.25 for minimum absolute
average log ratio per region, 10,000 for maximum number of
aberrant regions, and 3 consecutive probes with the same polarity
were required for the minimum number of probes per region.

UCSC Visualization
CNV and expression data were uploaded into the UCSC
Genomics Bioinformatics browser website (http://genome.ucsc.
edu/) in bed graph format according to the website instructions to
allow for graphic inspection of the data. Expression level was
based on comparison to tissue from normally developing
individuals as described previously [10,25].

Results and Discussion
Heart formation and function are precisely controlled by
networks of transcription factors that link upstream signaling
systems with the protein-coding genes required for cardiac
myogenesis, morphogenesis and contractility. Single gene defects
have been identified which cause CHDs, but they are rare. Thus,
most of the heritability of congenital heart defects remains to be
identified. Several reports examining CNVs associated with CHDs
to date have added several additional potential candidate genes/
regions that may contribute to dysregulated heart development,
but the resolution of these reports was limited to CNVs greater
than about 100 kb. Therefore, we created an ultra high-density
custom microarray focused on the genes known to be associated
with cardiovascular development and function. We placed genes
in three levels of importance based on potential impact on heart
development using current annotation regarding potential developmental significance for the heart.
Our primary objective was to search for CNVs that were
unlikely to be detected by previous assessments using standard
aCGH or GWAS. We found many small CNVs that have the
potential to impact the function of genes in our high priority list of
genes, as well as the much larger number in the second and third
tier genes. CNVs were detected for every chromosome within our
cohort of children with TOF. Using the criteria described in the
Methods section to identify CNVs, a total of 613 CNVs ranging
from 74 base pairs to 19.5 Mb were detected. These included 402
deletions with an average size of 511 kb, and 211 duplications with
an average size of 142 kb. We detected four CNVs larger than
5 Mb in size, and 216 that were less than 10 Kb. Summary
information about the distribution and size of CNVs is listed in
Table 1, and the specific distribution of these CNVs on individual
chromosomes is listed in Table S4 in Tables S3 and S4. The entire
list of CNVs is presented in Table S5 (the original aCGH files are
available upon request from the first corresponding author).
Among the CNVs detected in these 34 subjects, there were 16
subjects with 33 different CNVs involving 13 genes that are known
to be critical for regulating development of the right ventricle
making them good candidate genes for contributing to TOF (the
genes were identified using the GO terms right ventricle morphogenesis
or outflow track morphogenesis; Table 2). Two of these genes are
known to be pathogenic, JAG1 [18,29] and NOTCH1 [29], on
chromosomes 9 and 20 respectively. Additionally, there were 79
genes from the list of 591 validated genes (genes that were
experimentally determined to have a role in vertebrate heart
development or function extracted from IPA) that were partially or
completely contained in a CNV. Interestingly, all 34 individuals
examined had at least one CNV involving these 79 genes. See
Table S5 for a complete list of all CNVs detected.

Exon-level Expression Microarrays
We previously analyzed the gene expression patterns in 13 of
the subjects included in this genomic assessment. Detailed
descriptions of subjects used for expression analysis and array
preparation can be found in our previous publication [25]. Briefly,
RNA was extracted from ,10 mg of frozen right ventricular tissue
using a mirVana microRNA isolation kit (Applied Biosystems/
Ambion, Austin, TX) according to the manufactures instructions.
The exon-level expression arrays were Affymetrix HuEx-1_0-stv2 (Affymetrix, Santa Clara, CA), and the experimental data were
deposited in the Gene Expression Omnibus (GEO accession #
GSE35776). These file are embargoed until June 2014, however,
the files will be made available upon request prior to release from
embargo. All arrays were run at the Kansas University Medical
Center-Microarray Facility (KUMC-MF) according to the manufacturer’s protocols. The KUMC-MF is supported by the Kansas
University-School of Medicine, KUMC Biotechnology Support
Facility, the Smith Intellectual and Developmental Disabilities
Research Center (HD02528), and the Kansas IDeA Network of
Biomedical Research Excellence (RR016475). All analyses were
performed using statistical software: Partek Genomics Suite
software version 6.6 (Partek Inc, St. Louis). Raw data (CEL. files)
were uploaded into Partek Genomics Suite for normalization and
statistical analysis. Robust Multichip Analysis (RMA) was used for
background correction followed by quantile normalization with
baseline transformation to the median of the control samples.
Only probes with intensity values above 20% of background value,
in at least one of the conditions, were included for additional
analysis. The Ingenuity Pathways Analysis (IPA) version 9.0 was
used to explore networks, canonical pathways and predefined
functional categories. A Fisher’s exact test was used to calculate a
p-value determining the probability that the association between
the genes in the dataset and the pathway was explained by chance
alone. All biological functions and/or diseases in IPA’s database
were considered for the analysis without bias. Significance was
defined as a p-value #0.05.

Real-Time Quantitative Polymerase Chain Reaction (qPCR) and Quantitative Reverse Transcription-PCR (qRTPCR)
CNV status was validated by q-PCR performed on a subset of
genes/regions with copy number changes using specific primers
(genes and primers are listed in Table S3 in Tables S3 and S4) and
SYBR green as previously described [10,28]. Gene expression was
verified by qRT-PCR performed on a subset of genes using gene
specific primers (primers are listed in Table S3) and SYBR green
PLOS ONE | www.plosone.org
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Table 1. Summary of CNVs Detected in 34 Subjects using ultra-High Resolution CGH.

Duplicated CNVs

Deleted CNVs

Total CNVs

No. of CNVs

211

402

613

Range of CNVs (bp)

79–1,482,399

74–19,485,749

74–19,485,749

CNVs per individual

6.2

11.8

18.0
235,358,588

Overall

Total size (bp)

30,013,063

205,345,525

Average size per CNV (bp)

142,377

511,828

384,573

Average size per individual (bp)

1,158,165

1,423,255

2,581,420

No. of CNVs$5 Mb (bp)

0

4

4

doi:10.1371/journal.pone.0087472.t001

defects such as pulmonary stenosis and TOF [29,34–36]. Likewise,
NOTCH1 mutations have been shown to cause bicuspid aortic
valve (BAV), as well as TOF [8]. These large deletions would be
detected by standard aCGH, and are probable contributors to the
TOF of these two infants.
The interest in identifying risk factors for CHD has resulted in
recent large GWAS studies reporting significant associations
between SNPs located on chromosomes 12q24.11–13 and 13q32
[11], and 15q26.3 and 18q21.2 [12]. We did not see any of our
CNVs within or near these regions, with the exception of 15q26.3.
We observed one subject with a 126 kb duplication in this region
(see Table S5). However, it was detected by our background
probes, and only impacted 3 open reading frame sequences; not
within a target gene. This is an interesting coincidence, but is of
uncertain significance. Additionally, a recent case report of
somatic mutations that reduce the expression of GATA6 have
been associated with TOF [13]. We observed two deletions
involving part of GATA6, and this strengthens the link between
GATA6 and TOF.

Comparison to CNVs in Individuals without Heart Defects
Our custom gene centered array was not available for analysis
of subjects without heart defects. Therefore, in order to study
whether the CNVs we identified were present in individuals
without heart defects, we downloaded the datasets from Mills et al,
and Jiang et al [30,31]. These datasets were used for assessments
of small CNVs in 24 individuals from the Hapmap project [30],
and 32 individuals with autism [31] using genome sequencing
tools. The subjects in these two reports had no reported evidence
of heart defects. We eliminated SNPs and small indels less than
100 bp from our comparison. We manually searched the datasets
for CNVs involving the 13 genes from pathways regulating heart
development. We searched for small CNVs anywhere in the gene,
or 10 kb upstream or downstream, in order to include regions
where the CNV would be most likely to affect gene expression or
function. These comparison dataset searches were limited to
CNVs less than 10 kb (Table 2).
The dataset from Jiang et al [31] contained far more CNVs
than the Mills et al [30] dataset. This is undoubtedly due to
technical differences in the way the CNVs were identified, but may
also reflect the higher burden of CNVs in general, in individuals
with developmental disorders. Only one CNV involving our 13
critical genes did not have counterparts in the two comparison
datasets: HEY1, (Table 2). HEY1 is a member of the Notch
pathway, and is a transcription factor involved in determining cell
fate and boundary formation. There were 4 deletions and 3
duplications involving Hey1 in our cohort. Hey1 knockout mice had
no apparent phenotype, but the combined knockout of Hey1 and
Hey2 caused embryonic lethality due to inadequate vascular
remodeling [32]. Thus, Hey1/Hey2 are critical for cardiovascular
development. Therefore, alteration of the dosage of HEY1 in these
infants may have contributed to the inadequate communication
between the first and second heart field and thus resulted in TOF
and merits further investigation.

Inheritance
The CNVs containing JAG1, TBX2, GATA6 or NOTCH1were
particularly interesting because of their known association with
heart defects. Therefore, we tested these to determine whether
they were de novo or inherited. Each CNV had at least one case
that was inherited, and all but the CNV containing JAG1 had a
case that was de novo in origin (Table 2). Regardless of the origin
of the CNV, CNVs involving some or all of a gene could make
subtle differences in expression or function that could have
contributed to TOF, and certainly warrant further investigation.

CNVs in High Frequency in the TOF Cohort
Three CNVs containing genes associated with cardiovascular
development or function, but not known to directly regulate heart
development, occurred in high frequency in our cohort of infants
with TOF: CHL1, NKX2-1 and GSTT1. In addition to the above
mentioned datasets, we used the Database of Genomic Variants
(DGV, http://projects.tcag.ca/variation/) to search for additional
reports of CNVs involving these three genes in normal individuals.
These data are summarized in Table 2. Our cohort contained 19
CNVs (19 of 34; 56%) involving much of the promoter and the
first 2 exons of CHL1, and all 19 CNVs were deletions. Two
reports in the DGV indicated frequencies of 1 duplication in 30
subjects [37], and 2 duplications in 450 subjects [38]. In our
cohort there were 13 deletions involving part of NKX2-1 (13/34;
38%). The DGV contained one report with 2 deletions in 450
control subjects examined [38]. Finally, our cohort had 25 CNVs

Previously Identified Candidate Regions
One patient had a deletion encompassing JAG1, and a second
deletion encompassing NOTCH1. A second patient had a deletion
encompassing NOTCH1 (Table 2). The JAGGED genes (JAG1 and
JAG2) encode NOTCH ligands. NOTCH1 is one of four NOTCH
family receptors. NOTCH is an ancient cell-signaling system that
regulates cell fate via local cell-cell interactions, and can initiate
diverse and tissue-specific downstream effects such as cell fate
specification, progenitor cell maintenance, cell proliferation,
apoptosis and boundary formation [33]. JAG1 mutations have
been found in patients with Alagille syndrome which can include
TOF, and also in patients with non-syndromic right-sided heart
PLOS ONE | www.plosone.org
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Figure 1. Correlation between copy number and gene expression of GSTT1. GSTT1 expression in tissue from the right ventricle of infants
with TOF relative to controls. Pearson correlation coefficient; r = 0.95, p = 0.001.
doi:10.1371/journal.pone.0087472.g001

to allow conclusions to be made about the correlation between the
CNV and expression in the ventricular tissue.
GSTT1 was the only gene with a clear correlation between copy
number and gene expression in the RV (Pearson’s correlation
coefficient, r = 0.95, p = 0.001; 7 duplications, 2 deletions from the
13 subjects examined with expression arrays). Figure 1 shows the
relationship between GSTT1 copy number and gene expression in
the RV tissue of infants with TOF (compared to RV control
tissue). We uploaded the CGH data and the probe intensity data
to the UCSC browser to visualize the relationship between the
CNVs and probe level expression (Figure S1). The TOF subjects
without CNVs involving GSTT1 did not have significant changes
in GSTT1 expression when compared to the tissue from normally
developing controls. Those with deletions had significantly less
GSTT1 expression, and those with duplications had significantly
more expression of GSTT1 in the right ventricular tissue,
compared to normally developing subjects. This included all the
probes within the affected region (Figure S1). GSTT1 is the first
step in glutathione detoxification, and null genotypes of glutathione transferases have recently been associated with risk of CHD,
particularly when parents were exposed to environmental toxins
[40]. But since our cohort with TOF had individuals with underand over-expression of GSTT1 relative to control subjects, it seems
rather unlikely that CNVs involving GSTT1 represent a strong risk
factor for TOF.
In addition, we used qRT-PCR to examine the expression of 5
genes of particular relevance for heart development, TBX2 (3
duplications, 1 deletion), GATA6 (2 deletions), NOTCH1 (2
deletions), NOTCH2 (2 deletions) and JAG1 (1 deletion) in RV
tissue from subjects with CNVs involving these genes compared to
the pooled RNA from our control samples (data not shown). We
did not have exon expression microarrays on any of these subjects,
but extracted RNA from archived RV in order to examine
expression. Expression of NOTCH1, GATA6 and JAG1 did not
significantly differ from the expression of the control samples
regardless of CNV status. Interestingly, the expression of TBX2
and NOTCH2 were reduced in the RV tissue of all TOF subjects

involving GSTT1 (3 deletions and 22 duplications, 26/34; 76%).
The frequencies reported in the DGV were 21 deletions in 30
subjects [37], and 630 CNVs (301 deletions and 329 duplications)
in 1184 subjects [39]. The frequency of CNVs for these three
genes in our cohort were all significantly higher than those seen in
the DGV (chi square test of proportions, p,0.001) with the
exception of the CNVs involving GSTT1 compared to the
observed frequency reported by Perry et al [37] (our TOF cohort,
26/34 = 76%; Perry et al. 21/30 = 70%), which, although there
was a higher frequency in our cohort, it was not statistically
significant.
Although CNVs involving these genes are relatively common in
normal individuals, they occurred at a significantly higher
frequency in our cohort of subjects with TOF. These three genes
have no known direct influence on heart development. However,
within the context of accumulating ‘‘noise’’ in the communication
between the first and second heart field, alterations in the behavior
of these genes might contribute to the dysregulation that leads to
TOF.

Correlation between CNVs and Gene Expression
We had genome wide expression exon arrays available for 13 of
our subjects who also underwent gcCGH analysis. The expression
analysis was done using RNA extracted from right ventricular
tissue removed at the time of surgical correction of the defect
[10,25]. We examined the data from these two platforms to look
for correlations between CNVs and gene expression in the RV.
We used gene expression data at the probe (exon) level, as well as
the whole gene level, to test for CNV/expression correlation. We
limited our correlational assessment to CNVs associated with the
genes in the list of 591 validated genes. Each of the 13 subjects
with expression analysis had at least one CNV involving one or
more genes on the list. In these 13 subjects, there were a total of 79
CNVs meeting the inclusion criteria. There were 41 different
genes with a CNV encompassing part or all of the genes, never the
less, most of the genes within the CNVs occurred too infrequently
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for whom we examined expression data relative to the control
samples from normally developing infants. This no doubt reflects
other regulatory mechanisms that are independent of copy
number.
It should be emphasized that our expression data was limited in
scope to a small sample, and expression at 6 months of age may
not reflect expression during early gestation when the heart fields
were misaligned. In addition, subtle changes in expression that are
not within the resolution of our tools could be important for
precise regulation of early heart development.

cardiac tissues from infants with TOF relative to
controls as graphically displayed in the UCSC Genome
Browser.
(TIF)
Table S1 Patient Characteristics.

(XLSX)
Table S2 List of genes used to create the gene centric

array.
(XLSX)
Tables S3 and S4 Includes Table S3 and S4. Table S3.
Primers used for CNVs containing genes of primary importance
for heart development. Table S4. Summary of chromosomal
distribution of CNVs.
(PDF)

Conclusions
Our study was designed to examine structural variation at very
high resolution in genes with potential significance for heart
development or function. We identified a large number of
relatively small CNVs, not previously reported. With the possible
exception of the CNVs involving JAG1 and NOTCH1, our small
sample size precludes any conclusion about the broader impact of
these CNVs. However, it seems likely that some of these CNVs,
together with other genetic and epigenetic variants, and probably
environmental factors, may have contributed to the developmental
deficiency that caused TOF. Delineating the impact of multiple
small contributions to developmental irregularity remains a
challenge. However, new high-resolution technologies are aiding
in the identification of potentially important genetic elements that
may eventually provide a molecular genetic explanation for
complex developmental disorders like tetralogy of Fallot.

Table S5 Complete list of CNVs.

(XLS)

Acknowledgments
We thank Drs. Stephen Scherer and Ryan Yuen for providing their dataset
[31].

Author Contributions
Conceived and designed the experiments: DCB SY. Performed the
experiments: DCB NK SF. Analyzed the data: DCB XGZ NK JEO JM SY
HYL. Contributed reagents/materials/analysis tools: DCB SY SF HYL.
Wrote the paper: DCB XGZ SY.

Supporting Information
Figure S1 Representative examples of copy number
variants involving GSTT1 and expression of GSTT1 in

References
14. Breckpot J, Thienpont B, Arens Y, Tranchevent LC, Vermeesch JR, et al. (2011)
Challenges of interpreting copy number variation in syndromic and nonsyndromic congenital heart defects. Cytogenet Genome Res 135: 251–259.
15. Breckpot J, Thienpont B, Peeters H, de Ravel T, Singer A, et al. (2011) Array
comparative genomic hybridization as a diagnostic tool for syndromic heart
defects. J Pediatr 156: 810–817, 817 e811–817 e814.
16. Erdogan F, Larsen LA, Zhang L, Tumer Z, Tommerup N, et al. (2008) High
frequency of submicroscopic genomic aberrations detected by tiling path array
comparative genome hybridisation in patients with isolated congenital heart
disease. J Med Genet 45: 704–709.
17. Goldmuntz E, Paluru P, Glessner J, Hakonarson H, Biegel JA, et al. (2012)
Microdeletions and microduplications in patients with congenital heart disease
and multiple congenital anomalies. Congenit Heart Dis 6: 592–602.
18. Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, et al. (2009) De novo
copy number variants identify new genes and loci in isolated sporadic tetralogy
of Fallot. Nat Genet 41: 931–935.
19. Hitz MP, Lemieux-Perreault LP, Marshall C, Feroz-Zada Y, Davies R, et al.
(2012) Rare copy number variants contribute to congenital left-sided heart
disease. PLoS Genet 8: e1002903.
20. Silversides CK, Lionel AC, Costain G, Merico D, Migita O, et al. (2012) Rare
copy number variations in adults with tetralogy of Fallot implicate novel risk
gene pathways. PLoS Genet 8: e1002843.
21. Soemedi R, Wilson IJ, Bentham J, Darlay R, Topf A, et al. (2012) Contribution
of global rare copy-number variants to the risk of sporadic congenital heart
disease. Am J Hum Genet 91: 489–501.
22. Tomita-Mitchell A, Mahnke DK, Struble CA, Tuffnell ME, Stamm KD, et al.
(2012) Human gene copy number spectra analysis in congenital heart
malformations. Physiol Genomics 44: 518–541.
23. Manning M, Hudgins L, Professional P, Guidelines C (2010) Array-based
technology and recommendations for utilization in medical genetics practice for
detection of chromosomal abnormalities. Genet Med 12: 742–745.
24. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, et al. (2010)
Consensus statement: chromosomal microarray is a first-tier clinical diagnostic
test for individuals with developmental disabilities or congenital anomalies.
Am J Hum Genet 86: 749–764.
25. O’Brien JE, Jr., Kibiryeva N, Zhou XG, Marshall JA, Lofland GK, et al. (2012)
Noncoding RNA expression in myocardium from infants with tetralogy of Fallot.
Circ Cardiovasc Genet 5: 279–286.

1. Apitz C, Webb GD, Redington AN (2009) Tetralogy of Fallot. Lancet 374:
1462–1471.
2. Burn J, Brennan P, Little J, Holloway S, Coffey R, et al. (1998) Recurrence risks
in offspring of adults with major heart defects: results from first cohort of British
collaborative study. Lancet 351: 311–316.
3. Veldtman GR, Connolly HM, Grogan M, Ammash NM, Warnes CA (2004)
Outcomes of pregnancy in women with tetralogy of Fallot. J Am Coll Cardiol
44: 174–180.
4. Zellers TM, Driscoll DJ, Michels VV (1990) Prevalence of significant congenital
heart defects in children of parents with Fallot’s tetralogy. Am J Cardiol 65: 523–
526.
5. Bailliard F, Anderson RH (2009) Tetralogy of Fallot. Orphanet J Rare Dis 4: 2.
6. Roessler E, Ouspenskaia MV, Karkera JD, Velez JI, Kantipong A, et al. (2008)
Reduced NODAL signaling strength via mutation of several pathway members
including FOXH1 is linked to human heart defects and holoprosencephaly.
Am J Hum Genet 83: 18–29.
7. Pierpont ME, Basson CT, Benson DW, Jr., Gelb BD, Giglia TM, et al. (2007)
Genetic basis for congenital heart defects: current knowledge: a scientific
statement from the American Heart Association Congenital Cardiac Defects
Committee, Council on Cardiovascular Disease in the Young: endorsed by the
American Academy of Pediatrics. Circulation 115: 3015–3038.
8. Wessels MW, Willems PJ (2010) Genetic factors in non-syndromic congenital
heart malformations. Clin Genet 78: 103–123.
9. Rochais F, Mesbah K, Kelly RG (2009) Signaling pathways controlling second
heart field development. Circ Res 104: 933–942.
10. Bittel DC, Butler MG, Kibiryeva N, Marshall JA, Chen J, et al. (2011) Gene
expression in cardiac tissues from infants with idiopathic conotruncal defects.
BMC Med Genomics 4: 1.
11. Cordell HJ, Topf A, Mamasoula C, Postma AV, Bentham J, et al. (2013)
Genome-wide association study identifies loci on 12q24 and 13q32 associated
with tetralogy of Fallot. Hum Mol Genet 22: 1473–1481.
12. Flaquer A, Baumbach C, Pinero E, Garcia Algas F, de la Fuente Sanchez MA,
et al. (2013) Genome-wide linkage analysis of congenital heart defects using
MOD score analysis identifies two novel loci. BMC Genet 14: 44.
13. Huang RT, Xue S, Xu YJ, Yang YQ (2013) Somatic mutations in the GATA6
gene underlie sporadic tetralogy of Fallot. Int J Mol Med 31: 51–58.

PLOS ONE | www.plosone.org

6

January 2014 | Volume 9 | Issue 1 | e87472

CNVs in Tetralogy of Fallot

33. de la Pompa JL (2009) Notch signaling in cardiac development and disease.
Pediatr Cardiol 30: 643–650.
34. Colliton RP, Bason L, Lu FM, Piccoli DA, Krantz ID, et al. (2001) Mutation
analysis of Jagged1 (JAG1) in Alagille syndrome patients. Hum Mutat 17: 151–
152.
35. Krantz ID, Colliton RP, Genin A, Rand EB, Li L, et al. (1998) Spectrum and
frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their
families. Am J Hum Genet 62: 1361–1369.
36. Li L, Krantz ID, Deng Y, Genin A, Banta AB, et al. (1997) Alagille syndrome is
caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat
Genet 16: 243–251.
37. Perry GH, Ben-Dor A, Tsalenko A, Sampas N, Rodriguez-Revenga L, et al.
(2008) The fine-scale and complex architecture of human copy-number
variation. Am J Hum Genet 82: 685–695.
38. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, et al. (2010) Origins and
functional impact of copy number variation in the human genome. Nature 464:
704–712.
39. International HapMap C, Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM,
et al. (2010) Integrating common and rare genetic variation in diverse human
populations. Nature 467: 52–58.
40. Cresci M, Foffa I, Ait-Ali L, Pulignani S, Gianicolo EA, et al. (2011) Maternal
and paternal environmental risk factors, metabolizing GSTM1 and GSTT1
polymorphisms, and congenital heart disease. Am J Cardiol 108: 1625–1631.

26. Yu S, Bittel DC, Kibiryeva N, Zwick DL, Cooley LD (2009) Validation of the
Agilent 244 K oligonucleotide array-based comparative genomic hybridization
platform for clinical cytogenetic diagnosis. Am J Clin Pathol 132: 349–360.
27. Yu S, Kielt M, Stegner AL, Kibiryeva N, Bittel DC, et al. (2009) Quantitative
real-time polymerase chain reaction for the verification of genomic imbalances
detected by microarray-based comparative genomic hybridization. Genet Test
Mol Biomarkers 13: 751–760.
28. Bittel DC, Kibiryeva N, Sell SM, Strong TV, Butler MG (2007) Whole genome
microarray analysis of gene expression in Prader-Willi syndrome. Am J Med
Genet A 143: 430–442.
29. Bauer RC, Laney AO, Smith R, Gerfen J, Morrissette JJ, et al. (2010) Jagged1
(JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis. Hum
Mutat 31: 594–601.
30. Mills RE, Luttig CT, Larkins CE, Beauchamp A, Tsui C, et al. (2006) An initial
map of insertion and deletion (INDEL) variation in the human genome.
Genome Res 16: 1182–1190.
31. Jiang YH, Yuen RK, Jin X, Wang M, Chen N, et al. (2013) Detection of
clinically relevant genetic variants in autism spectrum disorder by whole-genome
sequencing. Am J Hum Genet 93: 249–263.
32. Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M (2004) The Notch
target genes Hey1 and Hey2 are required for embryonic vascular development.
Genes Dev 18: 901–911.

PLOS ONE | www.plosone.org

7

January 2014 | Volume 9 | Issue 1 | e87472

